Related Experiment Videos
In vivo activation of LAK cells during systemic IL-2 therapy
P Lang1, I Vitté-Mony, F Farace
1Institut Gustave Roussy, Villejuif, France.
European Cytokine Network
|August 1, 1990
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2025
Procaine hydrochloride improves DSS-induced colitis via inhibition of IL-6/STAT3 and FOXP3 methylation.
European cytokine network·2026
VEGFC as a prognostic cytokine biomarker linking lymph node metastasis to immune suppression in breast cancer.
European cytokine network·2026
Targeting the cytokine-epigenetic axis: a new paradigm and prospects for disease treatment.
European cytokine network·2026
Emerging viral infections: role of flavivirus NS1-mediated rewiring of PRR signaling.
European cytokine network·2026
Safety and antitumor activity of the first-in-class EGFR-HER3 bispecific antibody-drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase 1b study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Interleukin-10 in endometriosis: a systematic review of systemic and local immune compartment differences.
European journal of obstetrics, gynecology, and reproductive biology·2026
CBL0137 inhibits TFR2-mediated IgA1 deposition in IgA nephropathy.
International immunopharmacology·2026